Neuren Pharmaceuticals Limited has released a press release.
Q1 2020 Activity Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- First patent in Israel granted for trofinetide
- Temporary pause in new enrolments for LAVENDER trial in US
- Neuren to capture substantially greater value after Phase 3
- Compelling results for 2591 dose ranging study in PMS model
- Commentary on potential benefit to Neuren of RPD designation
Later from Neuren Pharmaceuticals
- Appendix 4C - quarterly
- Neuren commences first clinical trial for NNZ-2591
- Neuren announces changes to leadership team
- Temporary enrolment pause ended in Phase 3 trial in the US
- Neuren successfully completes $20m capital raising
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals